【摘要】 目的评估DNA倍体分析系统检测结合HR-HPV检测在宫颈癌及癌前病变筛查中的临床意义。方法随机选取2019年1 000例行宫颈活检及宫颈细胞学检查的标本,同时行DNA倍体分析系统检测和HR-HPV检测,并对结果进行统计学分析。结果 CIN I及以上的阳性检出率:HR-HPV阳性率67.6%～90.9%;DNA倍体分析结果阳性率5.3%～76.4%;HR-HPV+DNA倍体分析结果阳性率70.7%～100%。结论随着组织病理恶性度升高,HR-HPV及DNA倍体分析结果阳性率都有不同程度的升高。DNA倍体分析系统结合HR-HPV检测,可以提高宫颈癌及癌前病变的检出率,有效的提高检查的准确性。更多还原

【Abstract】 Objective To evaluate the clinical significance of DNA ploidy analysis system combined with HR-HPV detection in the screening of cervical cancer and precancerous lesions. Methods 1 000 samples of cervical biopsy and cervical cytology were randomly selected in 2019. DNA ploidy analysis system and HR-HPV test were performed at the same time, and the results were statistically analyzed. Results The CIN I and more positive detection rate: HR-HPV positive rate 67.6%～90.9%. The positive rate of DNA ploidy was 5.3%～76.4%. The positive rate of HR-HPV+DNA ploidy was 70.7%～100%. Conclusion With the increase of histopathological malignancy, the positive rate of HR-HPV and DNA ploidy analysis increased in different degrees. DNA ploidy analysis system combined with HR-HPV detection can improve the detection rate of cervical cancer and precancerous lesions, and effectively improve the accuracy of detection.更多还原